Generic versions of AstraZeneca’s blockbuster cholesterol drug Crestor would infringe valid patent claims, the U.S. Court of Appeals for the Federal Circuit ruled Dec. 14 (AstraZeneca UK Ltd. v. Aurobindo Pharma Ltd. (In re Rosuvastatin Calcium Patent Litigation), Fed. Cir., 2010-1460, 2010-1461, 2010-1462, 2010-1463, 2010-1464, 2010-1465, 2010-1466, 2010-1467, 2010-1468, 2010-1469, 2010-1470, 2010-1471, 2010-1472, 2010-1473, 12/14/12).
The generic makers’ Feb. 9 victory on one aspect of the case, related to methods of use, turned out to be short-lived. With the appellate court’s current decision on the chemical composition claims at issue, the manufacturers will have to wait until 2016 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.